|
|
News Breaks | | | | September 20, 2012 | | 05:58 EDT |  | RDY, GSK | Dr. Reddy’s launches Amoxicillin tablets, capsules, and oral suspension
Dr. Reddy’s Laboratories announced that is has launched Amoxicillin Tablets, Capsules, and Oral Suspension, a bioequivalent generic version of Amoxil, or Amoxicillin, Tablets, Capsules, and Oral Suspension in the US Market on Sept. 17, 2012. Amoxicillin Tablets 500 mg and 875 mg, Capsules 250 mg and 500 mg, and Oral Suspension 125 mg/5 ml, 200 mg/5 ml, 250 mg/5 ml, and 400 mg/5 ml are approved by the U.S. FDA. The Amoxil brand and generic Tablets 875 mg has U.S. sales of approximately $22.2M, Capsules has U.S. sales of approximately $67.2M, and Oral Suspension has U.S. sales of approximately $89.5M, all for the most recent twelve months ending June 2012 according to IMS Health. Amoxil is a registered trademark of GlaxoSmithKline (GSK) and is licensed to Dr. Reddy’s Laboratories. | |
|
News For RDY;GSK From The Last 14 Days Check below for free stories on RDY;GSK the last two weeks. |
|
|
| May 22, 2013 | | 08:25 EDT | | GSK | GlaxoSmithKline awarded up to $200M by U.S. to develop new antibiotics
 Subscribe for More Information | | | May 21, 2013 | | 07:44 EDT |  | GSK | Sachs Associates to host a forum
Subscribe for More Information | | | 07:07 EDT |  | GSK | Theravance pullback on Elan bid a buying opportunity, says Piper Jaffray
Subscribe for More Information | | | May 14, 2013 | | 07:24 EDT | | GSK | EBD Group to host a conference
BioTrinity 2013 is being held in Newbury, England on May 14-16. | | | 06:12 EDT |  | RDY | Dr. Reddy's Labs reports Q4 EPS 60c, one estimate 54c
Subscribe for More Information | | | May 13, 2013 | | 16:25 EDT |  | GSK | On The Fly: Closing Wrap
Stocks on Wall Street were little changed from their opening levels as investors weighed the potential end of the Fed's quantitative easing program against a better than expected report on retail sales. The Wall Street Journal's Jon Hilsenrath suggested in a report over the weekend that the Federal Reserve has mapped a QE exit strategy. The report paired with the retail sales data left the market lacking conviction in either direction today, as the averages spent the majority of the session range-bound near the flatline. ECONOMIC EVENTS: In the U.S., retail sales rose 0.1% in April, which beat expectations for a 0.3% decline. Retail sales excluding autos, gas, and building materials rose 0.6%, which was also better than expected. Business inventories were flat in March, versus expectations for a 0.3% gain. In Asia, Chinese factory output grew 9.3% annually in April, which was up from 8.9% in March but still missed expectations for a 9.5% growth rate. COMPANY NEWS: The Supreme Court ruled unanimously that Monsanto's (MON) patented genetically altered soybeans are protected and that farmers cannot use them to create new seeds without paying the company... Dell's (DELL) special committee publicly asked for more information from Carl Icahn and Southeastern Asset Management about their proposed leveraged recapitalization. This request follows television interviews by Icahn last Friday in which he discussed his Dell proposal, as well as a weekend report in Barron's saying the Icahn and Southeastern plan could be a better deal for shareholders. MAJOR MOVERS: Among the notable gainers was Theravance (THRX), up $6.26, or 17.92%, to $41.20 after Elan Corporation (ELN) bought a stake in the potential future royalty payments from four respiratory programs partnered with GlaxoSmithKline (GSK) in exchange for $1B in cash. Also higher was Tesla (TSLA), which rose $11.04, or 14.38%, to $87.80 in its third straight double-digit percentage gain following a better-than-expected earnings report last week. Among the noteworthy losers was Barnes & Noble (BKS), down $2.21, or 9.48%, to $21.10 after the blog InsiderMonkey disputed a previous report about Microsoft's (MSFT) interest in the bookseller's NOOK assets. Also lower was JoS. A. Bank (JOSB), down $3.31, or 7.16%, to $42.90 after the company's first quarter earnings view came in below expectations. INDICES: The Dow was down 26.81, or 0.18%, to 15,091.68; the Nasdaq was up 2.21, or 0.06%, to 3,438.79; and the S&P 500 was nearly unchanged at 1,633.77. | | | 12:20 EDT | | GSK | On The Fly: Midday Wrap
Subscribe for More Information | | | 05:44 EDT | | GSK | Elan provides additional information on Elan/Theravance agreement
Subscribe for More Information | | | 05:35 EDT | | GSK | Theravance, Elan enter into $1B royalty participation agreement
Subscribe for More Information | |
|
|
|
|
|
|
